|Articles|January 31, 2014

Cenduit

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

Image Credit: Adobe Stock Images/KHAN VECTOR CO.

Reasoning About Individual Drug Causality in a Multifactorial World

ByEytan Ellenberg, MD, MPH, PhD

January 9th 2026

Why Trial Competition Is Undermining AI-Driven Gains

ByLiz Beatty,Andy Studna, Senior Editor

January 9th 2026

ACT Brief: Recalibrating Trial Efficiency and Access, Verana-COTA Merge to Expand RWE Scale, and FDA Rejects Hetlioz Jet Lag Indication

ByAndy Studna, Senior Editor

January 9th 2026

© tippapatt - © tippapatt - stock.adobe.com

Verana Health Merges With COTA to Expand Real-World Data Capabilities Across Oncology and Specialty Care

ByAndy Studna, Senior Editor

January 8th 2026

Reframing Efficiency to Protect Patient Access in 2026

ByLiz Beatty,Andy Studna, Senior Editor

January 8th 2026

Cenduit

Newsletter

Related Content

Reasoning About Individual Drug Causality in a Multifactorial World

Why Trial Competition Is Undermining AI-Driven Gains

ACT Brief: Recalibrating Trial Efficiency and Access, Verana-COTA Merge to Expand RWE Scale, and FDA Rejects Hetlioz Jet Lag Indication

Verana Health Merges With COTA to Expand Real-World Data Capabilities Across Oncology and Specialty Care

Reframing Efficiency to Protect Patient Access in 2026

Trending on Applied Clinical Trials Online

Reasoning About Individual Drug Causality in a Multifactorial World

BostonGene Expands AI-Driven Oncology Collaborations with New AstraZeneca Deal

ACT Brief: Recalibrating Trial Efficiency and Access, Verana-COTA Merge to Expand RWE Scale, and FDA Rejects Hetlioz Jet Lag Indication

ACT Brief: EU Comparator Drug Sourcing Pressures, AI Expands Its Role in Oncology Trials, and Rethinking AI Value in Clinical Development

Why Trial Competition Is Undermining AI-Driven Gains